Camille L. Bedrosian

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.5K citations · Full text

C3 glomerulopathy: consensus report

Matthew C. Pickering, Vivette D. D’Agati, Carla Nester et al. · Kidney International · 2013 · 623 citations · Full text

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Christoph Licht, Larry A. Greenbaum, Petra Muus et al. · Kidney International · 2015 · 406 citations · Full text

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

Fádi Fakhouri, Maryvonne Hourmant, Josep M. Campistol et al. · American Journal of Kidney Diseases · 2016 · 298 citations · Full text

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino et al. · Kidney International · 2016 · 286 citations · Full text